Researchers from the Technical University of Denmark (DTU), led by Professor Timothy Patrick Jenkins, have successfully integrated a hybrid quantum-classical system from ORCA Computing into a generative AI workflow. The team used this approach to design novel peptides—short amino acid chains—that bind to specific proteins, a critical phase in creating vaccines and immunotherapies.

Laboratory validation proved that the quantum-enhanced model outperformed purely classical AI, particularly in scenarios where training data was scarce. This is especially significant for developing medical treatments for underserved populations in Africa and Asia, as current genetic datasets are heavily skewed toward Western populations.

Despite the success, the researchers noted that current quantum hardware remains limited in size and complexity, meaning they could not yet encode full-sized antibodies. However, the project serves as a proof-of-concept for near-term commercial applications of quantum computing in drug discovery.

Working with pooled funds and spare time, the DTU team now plans to apply this workflow to larger proteins and more advanced AI models. Professor Jenkins also intends to use the technology to design synthetic antidotes for snakebite venom and target neglected diseases that typically lack research funding.